TPST
Tempest TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TPST Profile
Tempest Therapeutics Inc
A clinical-stage biopharmaceutical company that develops molecular therapeutics to treat cancer by direct tumor-killing or activating tumor-specific immunity
Biological Technology
04/05/2011
04/30/2013
NASDAQ Stock Exchange
24
12-31
Common stock
2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005
--
Tempest Therapeutics Inc was founded on April 5, 2011. The Company is a clinical-stage oncology company focused on developing and advancing novel oral therapies for the treatment of solid tumors using a deep scientific understanding of cancer biology and medicinal chemistry. The company is advancing clinical trials of two product candidates, TPST-1120 and TPST-1495, which are believed to be the first clinical-stage molecules designed to inhibit their respective targets; and two preclinical projects, one of which may be the first to target TREX-1, a key cellular enzyme that regulates the innate immune response of tumors.
